{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:36Z","timestamp":1784557056252,"version":"3.55.0"},"reference-count":53,"publisher":"Bioscientifica","issue":"9","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is no consensus strategy for mineralocorticoid (MC) therapy titration in patients with primary adrenal insufficiency (PAI). We aim to measure serum fludrocortisone (sFC) and urine fludrocortisone (uFC) levels and to determine their utility, alongside clinical\/biochemical variables and treatment adherence to guide MC replacement dose titration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Multi-centre, observational, cross-sectional study on 41 patients with PAI on MC replacement therapy. sFC and uFC levels (measured by liquid chromatography-tandem mass spectrometry), plasma renin concentration (PRC), electrolytes (Na\n                      <jats:sup>+<\/jats:sup>\n                      , K\n                      <jats:sup>+<\/jats:sup>\n                      ), mean arterial blood pressure (MAP), total daily glucocorticoid (dGC) and MC (dMC) dose, and assessment of treatment adherence were incorporated into statistical models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed a close relationship between sFC and uFC (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.434,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005) and between sFC and the time from the last fludrocortisone dose (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u22120.355,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023). Total dMC dose was related to dGC dose (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.556,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), K\n                      <jats:sup>+<\/jats:sup>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u22120.388,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.013) as well as sFC (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.356,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022) and uFC (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.531,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). PRC was related to Na\n                      <jats:sup>+<\/jats:sup>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.517,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) and MAP (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u22120.427,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006), but not to MC dose, sFC or uFC. Regression analyses did not support a role for sFC, uFC or PRC measurements and confirmed K\n                      <jats:sup>+<\/jats:sup>\n                      (\n                      <jats:italic>B\u2009=\u2009<\/jats:italic>\n                      \u221244.593,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005) as the most important variable to guide dMC titration. Of the patients, 32% were non-adherent with replacement therapy. When adherence was inserted into the regression model, it was the only factor affecting dMC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>sFC and uFC levels are not helpful in guiding dMC titration. Treatment adherence impacts on clinical variables used to assess MC replacement and should be included as part of routine care in patients with PAI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-23-0059","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T10:49:04Z","timestamp":1688640544000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":8,"title":["Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy"],"prefix":"10.1530","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-5735","authenticated-orcid":true,"given":"Riccardo","family":"Pofi","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism and NIHR Oxford Biomedical Research Centre, Churchill Hospital, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bonaventura","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Duffy","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Immunology, Heartlands Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Maunsell","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shine","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-5417","authenticated-orcid":true,"given":"Andrea M","family":"Isidori","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-8533","authenticated-orcid":true,"given":"Jeremy W","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism and NIHR Oxford Biomedical Research Centre, Churchill Hospital, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Lancet","first-page":"2152","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","unstructured":"Charmandari ENicolaides NC & Chrousos GP. Adrenal insufficiency. Lancet20143832152\u20132167. (https:\/\/doi.org\/10.1016\/S0140-6736(1361684-0)"},{"key":"bib2","series-title":"Lancet. Diabetes and Endocrinology","first-page":"216","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","unstructured":"Bancos IHahner STomlinson J & Arlt W. Diagnosis and management of adrenal insufficiency. Lancet. Diabetes and Endocrinology20153216\u2013226. (https:\/\/doi.org\/10.1016\/S2213-8587(1470142-1)"},{"key":"bib3","series-title":"Lancet","first-page":"2194","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","unstructured":"El-Maouche DArlt W & Merke DP. Congenital adrenal hyperplasia. Lancet20173902194\u20132210. (https:\/\/doi.org\/10.1016\/S0140-6736(1731431-9)"},{"key":"bib4","series-title":"Endocrine Reviews","first-page":"245","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"21","author":"White","year":"2000","unstructured":"White PC & Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews200021245\u2013291. (https:\/\/doi.org\/10.1210\/edrv.21.3.0398)"},{"key":"bib5","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1642","article-title":"Clinical review: DHEA replacement for postmenopausal women","volume":"96","author":"Davis","year":"2011","unstructured":"Davis SRPanjari M & Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. Journal of Clinical Endocrinology and Metabolism2011961642\u20131653. (https:\/\/doi.org\/10.1210\/jc.2010-2888)"},{"key":"bib6","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3536","article-title":"Clinical review: the benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis","volume":"99","author":"Elraiyah","year":"2014","unstructured":"Elraiyah TSonbol MBWang ZKhairalseed TAsi NUndavalli CNabhan MAltayar OProkop LMontori VM, Clinical review: the benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism2014993536\u20133542. (https:\/\/doi.org\/10.1210\/jc.2014-2261)"},{"key":"bib7","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1679","article-title":"Should dehydroepiandrosterone be administered to women?","volume":"107","author":"Wierman","year":"2022","unstructured":"Wierman ME & Kiseljak-Vassiliades K. Should dehydroepiandrosterone be administered to women?Journal of Clinical Endocrinology and Metabolism20221071679\u20131685. (https:\/\/doi.org\/10.1210\/clinem\/dgac130)"},{"key":"bib8","series-title":"Annals of the New York Academy of Sciences","first-page":"573","article-title":"Biological effects of 9-alpha-fluorohydrocortisone and related halogenated steroids in animals","volume":"61","author":"Fried","year":"1955","unstructured":"Fried J. Biological effects of 9-alpha-fluorohydrocortisone and related halogenated steroids in animals. Annals of the New York Academy of Sciences195561573\u2013581. (https:\/\/doi.org\/10.1111\/j.1749-6632.1955.tb42509.x)"},{"key":"bib9","series-title":"British Journal of Clinical Pharmacology","first-page":"1509","article-title":"Pharmacokinetics of oral fludrocortisone in septic shock","volume":"82","author":"Polito","year":"2016","unstructured":"Polito AHamitouche NRibot MPolito ALaviolle BBellissant EAnnane D & Alvarez JC. Pharmacokinetics of oral fludrocortisone in septic shock. British Journal of Clinical Pharmacology2016821509\u20131516. (https:\/\/doi.org\/10.1111\/bcp.13065)"},{"key":"bib10","series-title":"Journal of Steroid Biochemistry","first-page":"321","article-title":"Circadian rhythm of plasma aldosterone and time dependent alterations of aldosterone regulators","volume":"20","author":"Takeda","year":"1984","unstructured":"Takeda RMiyamori IIkeda MKoshida HTakeda YYasuhara SMorise T & Takimoto H. Circadian rhythm of plasma aldosterone and time dependent alterations of aldosterone regulators. Journal of Steroid Biochemistry198420321\u2013323. (https:\/\/doi.org\/10.1016\/0022-4731(8490225-5)"},{"key":"bib11","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"364","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","unstructured":"Bornstein SRAllolio BArlt WBarthel ADon-Wauchope AHammer GDHusebye ESMerke DPMurad MHStratakis CA, Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism2016101364\u2013389. (https:\/\/doi.org\/10.1210\/jc.2015-1710)"},{"key":"bib12","series-title":"Best Practice and Research. Clinical Endocrinology and Metabolism","first-page":"17","article-title":"Mineralocorticoid substitution and monitoring in primary adrenal insufficiency","volume":"29","author":"Quinkler","year":"2015","unstructured":"Quinkler MOelkers WRemde H & Allolio B. Mineralocorticoid substitution and monitoring in primary adrenal insufficiency. Best Practice and Research. Clinical Endocrinology and Metabolism20152917\u201324. (https:\/\/doi.org\/10.1016\/j.beem.2014.08.008)"},{"key":"bib13","series-title":"European Journal of Epidemiology","first-page":"1045","article-title":"Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study","volume":"31","author":"Movahedi","year":"2016","unstructured":"Movahedi MCostello RLunt MPye SRSergeant JC & Dixon WG. Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. European Journal of Epidemiology2016311045\u20131055. (https:\/\/doi.org\/10.1007\/s10654-016-0167-1)"},{"key":"bib14","series-title":"Endocrine Practice","first-page":"469","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","unstructured":"Clore JN & Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocrine Practice200915469\u2013474. (https:\/\/doi.org\/10.4158\/EP08331.RAR)"},{"key":"bib15","series-title":"New England Journal of Medicine","first-page":"2547","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","unstructured":"Buckley L & Humphrey MB. Glucocorticoid-induced osteoporosis. New England Journal of Medicine20183792547\u20132556. (https:\/\/doi.org\/10.1056\/NEJMcp1800214)"},{"key":"bib16","series-title":"JAMA Internal Medicine","first-page":"743","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","unstructured":"Johannesdottir SAHorvath-Puho EDekkers OMCannegieter SCJorgensen JOEhrenstein VVandenbroucke JPPedersen L & Sorensen HT. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Internal Medicine2013173743\u2013752. (https:\/\/doi.org\/10.1001\/jamainternmed.2013.122)"},{"key":"bib17","series-title":"Endocrine","first-page":"507","article-title":"Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review","volume":"67","author":"Mongioi","year":"2020","unstructured":"Mongioi LMCondorelli RABarbagallo FLa Vignera S & Calogero AE. Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review. Endocrine202067507\u2013515. (https:\/\/doi.org\/10.1007\/s12020-020-02187-7)"},{"key":"bib18","series-title":"Nature Reviews. Endocrinology","article-title":"Adrenal gland: new dual-release hydrocortisone tablet for adrenal insufficiency","volume":"8","author":"Osorio","year":"2011","unstructured":"Osorio J. Adrenal gland: new dual-release hydrocortisone tablet for adrenal insufficiency. Nature Reviews. Endocrinology20118 67. (https:\/\/doi.org\/10.1038\/nrendo.2011.231)"},{"key":"bib19","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2998","article-title":"Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study","volume":"103","author":"Venneri","year":"2018","unstructured":"Venneri MAHasenmajer VFiore DSbardella EPofi RGraziadio CGianfrilli DPivonello CNegri MNaro F, Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study. Journal of Clinical Endocrinology and Metabolism20181032998\u20133009. (https:\/\/doi.org\/10.1210\/jc.2018-00346)"},{"key":"bib20","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1137","article-title":"A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia","volume":"100","author":"Mallappa","year":"2015","unstructured":"Mallappa ASinaii NKumar PWhitaker MJDaley LADigweed DEckland DJVan Ryzin CNieman LKArlt W, A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism20151001137\u20131145. (https:\/\/doi.org\/10.1210\/jc.2014-3809)"},{"key":"bib21","series-title":"Journal of Endocrinology","first-page":"R13","article-title":"Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy","volume":"246","author":"Minnetti","year":"2020","unstructured":"Minnetti MHasenmajer VPofi RVenneri MAAlexandraki KI & Isidori AM. Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy. Journal of Endocrinology2020246R13\u2013R31. (https:\/\/doi.org\/10.1530\/JOE-20-0066)"},{"key":"bib22","series-title":"Clinical Endocrinology","first-page":"499","article-title":"Mineralocorticoid replacement in Addison's disease","volume":"10","author":"Thompson","year":"1979","unstructured":"Thompson DGMason AS & Goodwin FJ. Mineralocorticoid replacement in Addison's disease. Clinical Endocrinology197910499\u2013506. (https:\/\/doi.org\/10.1111\/j.1365-2265.1979.tb02107.x)"},{"key":"bib23","series-title":"Lancet","first-page":"11","article-title":"Evidence that patients with Addison's disease are undertreated with fludrocortisone","volume":"1","author":"Smith","year":"1984","unstructured":"Smith SJMacGregor GAMarkandu NDBayliss JBanks RAPrentice MGDorrington-Ward P & Wise P. Evidence that patients with Addison's disease are undertreated with fludrocortisone. Lancet1984111\u201314. (https:\/\/doi.org\/10.1016\/s0140-6736(8490181-8)"},{"key":"bib24","series-title":"Journal of Clinical Endocrinology and Metabolism","article-title":"Plasma renin measurements are unrelated to mineralocorticoid replacement dose in patients with primary adrenal insufficiency","volume":"105","author":"Pofi","year":"2020","unstructured":"Pofi RPrete AThornton-Jones VBryce JAli SRFaisal Ahmed SBalsamo ABaronio FCannuccia AGuven A, Plasma renin measurements are unrelated to mineralocorticoid replacement dose in patients with primary adrenal insufficiency. Journal of Clinical Endocrinology and Metabolism2020105. (https:\/\/doi.org\/10.1210\/clinem\/dgz055)"},{"key":"bib25","series-title":"Klinische Wochenschrift","first-page":"607","article-title":"Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement","volume":"54","author":"Oelkers","year":"1976","unstructured":"Oelkers W & L'Age M. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement. Klinische Wochenschrift197654607\u2013612. (https:\/\/doi.org\/10.1007\/BF01469025)"},{"key":"bib26","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1411","article-title":"Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease","volume":"81","author":"Cohen","year":"1996","unstructured":"Cohen NGilbert RWirth ACasley D & Jerums G. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease. Journal of Clinical Endocrinology and Metabolism1996811411\u20131415. (https:\/\/doi.org\/10.1210\/jcem.81.4.8636343)"},{"key":"bib27","series-title":"Journal of Endocrinological Investigation","first-page":"111","article-title":"Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency","volume":"46","author":"Ceccato","year":"2023","unstructured":"Ceccato FTorchio MTizianel IPeleg Falb MBarbot MSabbadin CBetterle C & Scaroni C. Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency. Journal of Endocrinological Investigation202346111\u2013122. (https:\/\/doi.org\/10.1007\/s40618-022-01889-1)"},{"key":"bib28","series-title":"Clinical Trials","first-page":"195","article-title":"Adherence reporting in randomized controlled trials","volume":"11","author":"Zhang","year":"2014","unstructured":"Zhang ZPeluso MJGross CPViscoli CM & Kernan WN. Adherence reporting in randomized controlled trials. Clinical Trials201411195\u2013204. (https:\/\/doi.org\/10.1177\/1740774513512565)"},{"key":"bib29","series-title":"Trials","article-title":"Nonadherence to treatment protocol in published randomised controlled trials: a review","volume":"13","author":"Dodd","year":"2012","unstructured":"Dodd SWhite IR & Williamson P. Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials201213 84. (https:\/\/doi.org\/10.1186\/1745-6215-13-84)"},{"key":"bib30","series-title":"Clinical Pharmacology and Therapeutics","first-page":"615","article-title":"Clinical pharmacology of the anti-inflammatory steroids","volume":"2","author":"Liddle","year":"1961","unstructured":"Liddle GW. Clinical pharmacology of the anti-inflammatory steroids. Clinical Pharmacology and Therapeutics19612615\u2013635. (https:\/\/doi.org\/10.1002\/cpt196125615)"},{"key":"bib31","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3266","article-title":"S. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","unstructured":"Funder JWCarey RMFardella CGomez-Sanchez CEMantero FStowasser MYoung WFJrMontori VM & Endocrine Society. S. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism2008933266\u20133281. (https:\/\/doi.org\/10.1210\/jc.2008-0104)"},{"key":"bib32","series-title":"Steroids","first-page":"555","article-title":"A sensitive radioimmunoassay for fludrocortisone in human plasma","volume":"59","author":"Mitsky","year":"1994","unstructured":"Mitsky VPWorkman RJNicholson WEVernikos JRobertson RM & Robertson D. A sensitive radioimmunoassay for fludrocortisone in human plasma. Steroids199459555\u2013558. (https:\/\/doi.org\/10.1016\/0039-128x(9490074-4)"},{"key":"bib33","series-title":"AAPS Journal","first-page":"727","article-title":"Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers","volume":"19","author":"Hamitouche","year":"2017","unstructured":"Hamitouche NComets ERibot MAlvarez JCBellissant E & Laviolle B. Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers. AAPS Journal201719727\u2013735. (https:\/\/doi.org\/10.1208\/s12248-016-0041-9)"},{"key":"bib34","series-title":"Biomedical Chromatography","first-page":"1213","article-title":"A highly sensitive method for the quantification of fludrocortisone in human plasma using ultra-high-performance liquid chromatography tandem mass spectrometry and its pharmacokinetic application","volume":"29","author":"Banda","year":"2015","unstructured":"Banda JLakshmanan RVvs SPGudla SP & Prudhivi R. A highly sensitive method for the quantification of fludrocortisone in human plasma using ultra-high-performance liquid chromatography tandem mass spectrometry and its pharmacokinetic application. Biomedical Chromatography2015291213\u20131219. (https:\/\/doi.org\/10.1002\/bmc.3410)"},{"key":"bib35","series-title":"European Journal of Endocrinology","first-page":"R165","article-title":"Therapy of endocrine disease: perspectives on the management of adrenal insufficiency: clinical insights from across Europe","volume":"169","author":"Grossman","year":"2013","unstructured":"Grossman AJohannsson GQuinkler M & Zelissen P. Therapy of endocrine disease: perspectives on the management of adrenal insufficiency: clinical insights from across Europe. European Journal of Endocrinology2013169R165\u2013R175. (https:\/\/doi.org\/10.1530\/EJE-13-0450)"},{"key":"bib36","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"4882","article-title":"Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry","volume":"94","author":"Erichsen","year":"2009","unstructured":"Erichsen MMLovas KSkinningsrud BWolff ABUndlien DESvartberg JFougner KJBerg TJBollerslev JMella B, Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. Journal of Clinical Endocrinology and Metabolism2009944882\u20134890. (https:\/\/doi.org\/10.1210\/jc.2009-1368)"},{"key":"bib37","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"376","article-title":"Primary adrenal insufficiency: managing mineralocorticoid replacement therapy","volume":"103","author":"Esposito","year":"2018","unstructured":"Esposito DPasquali D & Johannsson G. Primary adrenal insufficiency: managing mineralocorticoid replacement therapy. Journal of Clinical Endocrinology and Metabolism2018103376\u2013387. (https:\/\/doi.org\/10.1210\/jc.2017-01928)"},{"key":"bib38","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"259","article-title":"Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone","volume":"75","author":"Oelkers","year":"1992","unstructured":"Oelkers WDiederich S & Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. Journal of Clinical Endocrinology and Metabolism199275259\u2013264. (https:\/\/doi.org\/10.1210\/jcem.75.1.1320051)"},{"key":"bib39","series-title":"Journal of Endocrinological Investigation","first-page":"87","article-title":"Mineralocorticoids in the management of primary adrenocortical insufficiency","volume":"14","author":"Jadoul","year":"1991","unstructured":"Jadoul MFerrant ADe Plaen JF & Crabbe J. Mineralocorticoids in the management of primary adrenocortical insufficiency. Journal of Endocrinological Investigation19911487\u201391. (https:\/\/doi.org\/10.1007\/BF03350272)"},{"key":"bib40","series-title":"Clinica Chimica Acta","first-page":"109","article-title":"Human plasma quantification of fludrocortisone using liquid chromatography coupled with atmospheric pressure chemical ionization mass spectrometry after low-dosage administration","volume":"420","author":"Ribot","year":"2013","unstructured":"Ribot MPolito AGrassin-Delyle SAnnane D & Alvarez JC. Human plasma quantification of fludrocortisone using liquid chromatography coupled with atmospheric pressure chemical ionization mass spectrometry after low-dosage administration. Clinica Chimica Acta2013420109\u2013113. (https:\/\/doi.org\/10.1016\/j.cca.2012.11.026)"},{"key":"bib41","series-title":"Endocrinology","first-page":"107","article-title":"Studies concerning the regulation and importance of plasma angiotensinogen concentration in the dog","volume":"93","author":"Reid","year":"1973","unstructured":"Reid IATu WHOtsuka KAssaykeen TA & Ganong WF. Studies concerning the regulation and importance of plasma angiotensinogen concentration in the dog. Endocrinology197393107\u2013114. (https:\/\/doi.org\/10.1210\/endo-93-1-107)"},{"issue":"Supplement D","key":"bib42","series-title":"European Heart Journal Supplements","first-page":"D2","article-title":"Why do we need observational studies of everyday patients in the real-life setting?: Table","volume":"17","author":"Cohen","year":"2015","unstructured":"Cohen ATGoto SSchreiber K & Torp-Pedersen C. Why do we need observational studies of everyday patients in the real-life setting?: Table. European Heart Journal Supplements201517(Supplement D) D2\u2013D8. (https:\/\/doi.org\/10.1093\/eurheartj\/suv035)"},{"issue":"Supplement D","key":"bib43","series-title":"European Heart Journal Supplements","first-page":"D9","article-title":"Harnessing the power of real-life data","volume":"17","author":"Cox","year":"2015","unstructured":"Cox JL & Pieper K. Harnessing the power of real-life data. European Heart Journal Supplements201517(Supplement D) D9\u2013D14. (https:\/\/doi.org\/10.1093\/eurheartj\/suv036)"},{"key":"bib44","series-title":"Clinical Medicine","first-page":"258","article-title":"Adrenal insufficiency - recognition and management","volume":"17","author":"Pazderska","year":"2017","unstructured":"Pazderska A & Pearce SH. Adrenal insufficiency - recognition and management. Clinical Medicine201717258\u2013262. (https:\/\/doi.org\/10.7861\/clinmedicine.17-3-258)"},{"key":"bib45","series-title":"New England Journal of Medicine","first-page":"487","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","unstructured":"Osterberg L & Blaschke T. Adherence to medication. New England Journal of Medicine2005353487\u2013497. (https:\/\/doi.org\/10.1056\/NEJMra050100)"},{"key":"bib46","series-title":"BioMed Research International","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","unstructured":"Lam WY & Fresco P. Medication adherence measures: an overview. BioMed Research International20152015 217047. (https:\/\/doi.org\/10.1155\/2015\/217047)"},{"key":"bib47","series-title":"European Journal of Clinical Pharmacology","first-page":"1607","article-title":"Validation of self-reported adherence in chronic patients visiting pharmacies and factors associated with the overestimation and underestimation of good adherence","volume":"76","author":"Vald\u00e9s Y Llorca","year":"2020","unstructured":"Vald\u00e9s Y Llorca CCortes-Castell ERibera-Casado JMde Lucas-Ramos Pde Palacio-Guerrero LMMugarza-Borque FCasteig-Ayestaran JLDiaz-Olmo JCasteig-Blanco AGil-Guillen VF, Validation of self-reported adherence in chronic patients visiting pharmacies and factors associated with the overestimation and underestimation of good adherence. European Journal of Clinical Pharmacology2020761607\u20131614. (https:\/\/doi.org\/10.1007\/s00228-020-02950-9)"},{"key":"bib48","series-title":"Clinical Endocrinology","first-page":"753","article-title":"Assessment of medication adherence in children and adults with congenital adrenal hyperplasia and the impact of knowledge and self-management","volume":"94","author":"Ekbom","year":"2021","unstructured":"Ekbom KStrandqvist ALajic SHirschberg ALFalhammar H & Nordenstrom A. Assessment of medication adherence in children and adults with congenital adrenal hyperplasia and the impact of knowledge and self-management. Clinical Endocrinology202194753\u2013764. (https:\/\/doi.org\/10.1111\/cen.14398)"},{"key":"bib49","series-title":"JAMA","first-page":"2461","article-title":"Interventions to improve medication adherence: a review","volume":"320","author":"Kini","year":"2018","unstructured":"Kini V & Ho PM. Interventions to improve medication adherence: a review. JAMA20183202461\u20132473. (https:\/\/doi.org\/10.1001\/jama.2018.19271)"},{"key":"bib50","series-title":"BMC Health Services Research","article-title":"Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss","volume":"12","author":"Meddings","year":"2012","unstructured":"Meddings JKerr EAHeisler M & Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Services Research201212 270. (https:\/\/doi.org\/10.1186\/1472-6963-12-270)"},{"key":"bib51","series-title":"European Journal of Endocrinology","first-page":"309","article-title":"Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia","volume":"178","author":"Jenkins-Jones","year":"2018","unstructured":"Jenkins-Jones SParviainen LPorter JWithe MWhitaker MJHolden SEMorgan CLCurrie CJ & Ross RJM. Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia. European Journal of Endocrinology2018178309\u2013320. (https:\/\/doi.org\/10.1530\/EJE-17-0895)"},{"key":"bib52","series-title":"Korean Journal of Pediatrics","first-page":"31","article-title":"Management issues of congenital adrenal hyperplasia during the transition from pediatric to adult care","volume":"60","author":"Choi","year":"2017","unstructured":"Choi JH & Yoo HW. Management issues of congenital adrenal hyperplasia during the transition from pediatric to adult care. Korean Journal of Pediatrics20176031\u201337. (https:\/\/doi.org\/10.3345\/kjp.2017.60.2.31)"},{"key":"bib53","series-title":"Kidney International","first-page":"263","article-title":"Escape from the sodium-retaining effects of mineralocorticoids","volume":"17","author":"Knox","year":"1980","unstructured":"Knox FGBurnett JCJrKohan DESpielman WS & Strand JC. Escape from the sodium-retaining effects of mineralocorticoids. Kidney International198017263\u2013276. (https:\/\/doi.org\/10.1038\/ki.1980.32)"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/9\/EC-23-0059.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/9\/EC-23-0059.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/9\/EC-23-0059.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:23Z","timestamp":1784555183000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":53,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1530\/ec-23-0059","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}